People with hemophilia A do not produce adequate amounts of factor VIII, which is necessary to effectively clot blood. Without enough factor VIII, patients can experience spontaneous, uncontrolled internal bleeding that is painful, debilitating and damaging to joints. If untreated, patients with severe hemophilia A have a greatly reduced life expectancy.
According to the World Health Organization, more than 400,000 people in the world may have hemophilia A and it affects 15-20 of every 100,000 males born worldwide. People with hemophilia A infuse themselves with clotting factors three times a month, on average, unless they are on a preventive regimen, in which case their physician may prescribe infusing a therapy as often as three or four times per week.
ABOUT BAXTER
Baxter Healthcare Corporation is the principal domestic operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists health-care professionals and their patients with treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.
Questions and Answers
What are the labeling differences between RECOMBINATE and ADVATE?
ADVATE is derived from the same full-length molecule as RECOMBINATE and, therefore, has a similar label and indication. However, ADVATE offers greater convenience based on its higher potency and lower infusion volume, as well as the safety of its innovative plasma/albumin-free process.
Will ADVATE be priced higher than RECOMBINATE?
ADVATE is priced slightly higher than RECOMBINATE, but within the range of existing recombinant factor VIII therapies. This is based on the fact that ADVATE is the most advanced hemophilia therapy available, combinin
'"/>
Contact: Cindy Resman, BAXTER
847-948-2815
Porter Novelli
28-Jul-2003